Evidence map›Paper›PMID 22388628›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2012

Somatostatin receptor SPECT.

Giovanna Pepe, Roy Moncayo, Emilio Bombardieri, Arturo Chiti

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. [Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  5. Review
  6. Article
  7. Biomarkers in preclinical cancer imaging.European journal of nuclear medicine and molecular imaging · 2015
    Review
  8. Review
  9. Reply to comment on Pepe et al.: Somatostatin receptor SPECT.European journal of nuclear medicine and molecular imaging · 2013
    Article
  10. Article
  11. Comment on Pepe et al.: somatostatin receptor SPECT.European journal of nuclear medicine and molecular imaging · 2012
    Article
  12. Radiolabelled peptides in diagnosis and therapy: an introduction.European journal of nuclear medicine and molecular imaging · 2012
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Giovanna PepeNuclear Medicine, IRCCS Humanitas, Milan, Italy.
Roy Moncayo
Emilio Bombardieri
Arturo Chiti
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversität Innsbruck · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Somatostatin is a peptide with a broad distribution in the nervous system and acts as a neurotransmitter in several organs, having a wide range of mainly inhibiting effects, such as the suppression of growth hormone release, as well as the inhibition of pancreatic and gastrointestinal hormone release. Five somatostatin receptor subtypes have been cloned and demonstrated to have an emphasized expression in all human tumours. In particular, type 2 receptors were identified as the most frequently represented on the surface of neuroendocrine tumour cells, providing the molecular basis for many clinical applications of somatostatin analogues. Towards the end of the 1980s, the in vivo demonstration of somatostatin receptors on the surface of some tumours raised interest in receptor imaging, and indeed the peptide receptor overexpression on tumour cells, as compared to normal tissues, constitutes the basis for molecular imaging of these tumours. This review intends to illustrate the development of single photon emission radiopharmaceuticals for the study of somatostatin receptors and their application in diagnostic imaging.

Indexed as

RadiopharmaceuticalsCarcinoid TumorDigestive System NeoplasmsFemaleHumansIsotope LabelingLung NeoplasmsMaleNeoplasmsNeuroendocrine TumorsOctreotideParagangliomaPeptidesPheochromocytomaPituitary NeoplasmsReceptors, SomatostatinOctreotidePeptidesRadiopharmaceuticalsReceptors, SomatostatinSomatostatin

Identifiers

PMID22388628
OpenAlexW2098817226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.